Created at	Source	Raw Value	Validated value
March 11, 2022, 3:30 p.m.	oms	The expected primary outcome is safety in the use of intravenously infused CTM-TCU suspension in patients with pneumonia caused by SARS-CoV-2.	The expected primary outcome is safety in the use of intravenously infused CTM-TCU suspension in patients with pneumonia caused by SARS-CoV-2.